Congress opens addiction treatment to remote prescribing, removing travel barriers
H.R. 1627 — TREATS Act · Filed by Donald Norcross (D-NJ) · 31 cosponsors · Introduced Feb 26, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the Controlled Substances Act to allow doctors to conduct telehealth evaluations (remote video or phone consultations) as an alternative to in-person visits when prescribing FDA-approved addiction medications in schedules III–V. Currently, federal law requires at least one in-person medical evaluation before any controlled-substance prescription for substance use disorder; this bill permits that first evaluation to happen via telehealth instead, removing a barrier to remote addiction treatment.
Why we flagged it
The bill's operative mechanism is a straightforward removal of a federal barrier to remote addiction treatment. It expands access to FDA-approved medications for substance use disorder by permitting telehealth for the initial evaluation, consistent with modern telemedicine practice and public-health goals around addiction treatment.
What the text implies
- State law still governs telehealth practice standards and prescriber licensing; this bill does not preempt state restrictions, so access gains depend on state-level adoption and regulatory clarity.
- The bill permits telehealth only for FDA-approved addiction medications in schedules III–V; it does not extend to schedule II substances (e.g., buprenorphine in some formulations) or non-controlled addiction treatments, leaving some treatment pathways unchanged.
The full analysis lists 3 implications of this text.
Who stands to gain
telehealth platforms and providers offering addiction treatment services; healthcare systems and clinics expanding remote addiction-medicine capacity